Results 241 to 250 of about 14,200 (285)
Some of the next articles are maybe not open access.
Journal of Drug Delivery Science and Technology, 2023
Mayank Kumar Malik +3 more
semanticscholar +1 more source
Mayank Kumar Malik +3 more
semanticscholar +1 more source
Design of mesalamine loaded micro-particles: Preparation, in vitro and in-vivo characterization
Materials Today: Proceedings, 2023Laith Hamza Sameina +4 more
semanticscholar +1 more source
Connecticut medicine, 2010
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Reviews in gastroenterological disorders, 2006
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source

